series-b
Stage
2020
Founded
3
Investors
About
ArriVent is a clinical-stage biopharmaceutical company focused on the global development of innovative cancer therapies, particularly targeting EGFR mutations in non-small cell lung cancer through its lead drug firmonertinib.
Explore ArriVent's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.